Many programs begin with strong biological findings but struggle to translate early hits, fragments, or tool compounds into viable lead candidates. This is often due to limited medicinal chemistry resources and insufficient insight into the challenges of advancing a lead toward a drug candidate and generating the data required to secure seed funding.

Oxeltis address this by:
• Seamless integration of in silico design (CADD, SBDD, LBDD, AI/ML) with high-quality synthesis, in partnership with Molecular Forecaster (Montreal) and Assay development/in vitro biological screening in partnership with Partex.AI.Labs
• Rapid hit-to-lead and lead optimization, with a track record of delivering high-quality compounds efficiently and a highly skill team of chemists (50% Ph.D., 50% M.Sc.)
• Expertise in complex and enabling chemistries, supported by our hybrid SFC platform for rapid purification and scale-up (up to 25g/day) of chiral/achiral mixtures.
• Comprehensive biological services, including assay design, in vitro screening, and early pharmacology profiling, integrated with chemistry to accelerate DMTA cycles and decision-making.